Search research articles
Contact Us
Filters
Showing results (301-310 of 313) with videos related to
Page
of 32
Sort By:
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik
|
November 1, 2011
Development and characterization of genomic and expressed SSRs for levant cotton (Gossypium herbaceum L.)
Satya Narayan Jena, Anukool Srivastava, Krishan Mohan Rai, et al.
Oncogene
|
March 6, 2021
Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
Reem Ali, Adel Alblihy, Islam M Miligy, et al.
Oncogene
|
February 6, 2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers
Mengxiong Wang, Renan B Ferreira, Mary E Law, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Discovery of a novel class of AKT pleckstrin homology domain inhibitors
Daruka Mahadevan, Garth Powis, Eugene A Mash, et al.
South Asian Journal of Cancer
|
December 22, 2025
A Study of Molecular Subtypes (Profile) of Colorectal Cancer and Their Correlation with Clinical and Pathological Profile in a Tertiary Care Center in India
Srujana Joga, Sumit Goyal, Anurag Mehta, et al.
NAR Cancer
|
January 23, 2023
EEPD1 promotes repair of oxidatively-stressed replication forks
Aruna S Jaiswal, Hyun-Suk Kim, Orlando D Schärer, et al.
Journal of Cellular Physiology
|
December 31, 2008
Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer
Christine J Ye, Joshua B Stevens, Guo Liu, et al.
Frontiers in Nutrition
|
July 5, 2023
Effect of the SPRING home visits intervention on early child development and growth in rural India and Pakistan: parallel cluster randomised controlled trials
Betty R Kirkwood, Siham Sikander, Reetabrata Roy, et al.
Biorxiv : the Preprint Server for Biology
|
September 2, 2025
CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics
|
April 21, 2026
CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 313) with videos related to
Sort By:
Page
of 32
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik
|
November 1, 2011
Development and characterization of genomic and expressed SSRs for levant cotton (Gossypium herbaceum L.)
Satya Narayan Jena, Anukool Srivastava, Krishan Mohan Rai, et al.
Oncogene
|
March 6, 2021
Molecular disruption of DNA polymerase β for platinum sensitisation and synthetic lethality in epithelial ovarian cancers
Reem Ali, Adel Alblihy, Islam M Miligy, et al.
Oncogene
|
February 6, 2019
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers
Mengxiong Wang, Renan B Ferreira, Mary E Law, et al.
Molecular Cancer Therapeutics
|
September 16, 2008
Discovery of a novel class of AKT pleckstrin homology domain inhibitors
Daruka Mahadevan, Garth Powis, Eugene A Mash, et al.
South Asian Journal of Cancer
|
December 22, 2025
A Study of Molecular Subtypes (Profile) of Colorectal Cancer and Their Correlation with Clinical and Pathological Profile in a Tertiary Care Center in India
Srujana Joga, Sumit Goyal, Anurag Mehta, et al.
NAR Cancer
|
January 23, 2023
EEPD1 promotes repair of oxidatively-stressed replication forks
Aruna S Jaiswal, Hyun-Suk Kim, Orlando D Schärer, et al.
Journal of Cellular Physiology
|
December 31, 2008
Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer
Christine J Ye, Joshua B Stevens, Guo Liu, et al.
Frontiers in Nutrition
|
July 5, 2023
Effect of the SPRING home visits intervention on early child development and growth in rural India and Pakistan: parallel cluster randomised controlled trials
Betty R Kirkwood, Siham Sikander, Reetabrata Roy, et al.
Biorxiv : the Preprint Server for Biology
|
September 2, 2025
CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Molecular Cancer Therapeutics
|
April 21, 2026
CerS2 is a druggable target in triple-negative breast cancer
Hissah Alatawi, Haritha H Nair, Lingbao Ai, et al.
Page
of 32